Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Compare

393 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KYMR Analyst Ratings

Strong Buy

21 Buy

0 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Kymera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$110.50

▲(25.84% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $110.50 with a high forecast of $138.00 and a low forecast of $68.00. The average price target represents a 25.84% change from the last price of $87.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","139":"$139","52.75":"$52.8","81.5":"$81.5","110.25":"$110.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$138.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$110.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,52.75,81.5,110.25,139],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.86,72.3323076923077,77.80461538461539,83.27692307692308,88.74923076923076,94.22153846153847,99.69384615384615,105.16615384615385,110.63846153846154,116.11076923076924,121.58307692307693,127.05538461538461,132.5276923076923,{"y":138,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.86,70.21692307692308,73.57384615384615,76.93076923076923,80.28769230769231,83.64461538461538,87.00153846153846,90.35846153846154,93.71538461538461,97.07230769230769,100.42923076923077,103.78615384615384,107.14307692307692,{"y":110.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.86,66.94769230769231,67.03538461538461,67.12307692307692,67.21076923076923,67.29846153846154,67.38615384615385,67.47384615384615,67.56153846153846,67.64923076923077,67.73692307692308,67.82461538461538,67.91230769230769,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$138.00

Average Price Target$110.50

Lowest Price Target$68.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Catanzaro

Mizuho Securities

$81→$120

Buy

36.66%

Upside

Reiterated

12/11/25

Kymera Therapeutics price target raised to $120 from $81 at MizuhoKymera Therapeutics price target raised to $120 from $81 at Mizuho

Sudan Loganathan

Stephens

$65→$110

Buy

25.27%

Upside

Reiterated

12/11/25

Kymera Therapeutics price target raised to $110 from $65 at StephensKymera Therapeutics price target raised to $110 from $65 at Stephens

Brian Cheng

J.P. Morgan

$70→$125

Buy

42.35%

Upside

Reiterated

12/10/25

Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating

Andrew Fein

H.C. Wainwright

$84→$134

Buy

52.60%

Upside

Reiterated

12/09/25

Kymera Therapeutics' KT-621: Promising Oral Treatment for Atopic Dermatitis and Asthma Expansion PotentialValuation and Risks. Given the magnitude of FeNO reduction in comorbid asthma patients, we now include KT-621 in asthma in our valuation and revisited our PoS assumptions in AD which increases our PT to $134 from $84. For Asthma, we assume moderate to severe uncontrolled asthma patients in US to be around 2.5M of which we assume around 1M to be biologic eligible. the launch we project a probability adjusted revenue of $12M growing to $1.5B by 2034.

Derek Archila

Wells Fargo

$69→$116

Buy

32.10%

Upside

Reiterated

12/09/25

Kymera Therapeutics price target raised to $116 from $69 at Wells FargoKymera Therapeutics price target raised to $116 from $69 at Wells Fargo

Srikripa Devarakonda

Truist Financial

$80→$116

Buy

32.10%

Upside

Reiterated

12/09/25

Kymera Therapeutics (KYMR) Gets a Buy from Truist Financial

Geoff Meacham

Citi

$80→$110

Buy

25.27%

Upside

Reiterated

12/09/25

Kymera Therapeutics price target raised to $110 from $80 at CitiKymera Therapeutics price target raised to $110 from $80 at Citi

Judah Frommer

Morgan Stanley

$73→$127

Buy

44.63%

Upside

Reiterated

12/09/25

Morgan Stanley Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)Given the size of these addressable populations, these changes take our 12‐month PT to $127 (vs. $73 prior).

Jeff Jones

Oppenheimer

$67→$120

Buy

36.66%

Upside

Reiterated

12/09/25

Kymera Therapeutics (KYMR) Receives a Buy from Oppenheimer

Clara Dong

Jefferies

$73→$122

Buy

38.94%

Upside

Reiterated

12/09/25

Kymera Therapeutics price target raised to $122 from $73 at JefferiesKymera Therapeutics price target raised to $122 from $73 at Jefferies

Edward Tenthoff

Piper Sandler

$98→$125

Buy

42.35%

Upside

Reiterated

12/09/25

Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Etzer Darout

Barclays

$70→$119

Buy

35.52%

Upside

Reiterated

12/08/25

Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

Faisal Khurshid

Leerink Partners

$70→$118

Buy

34.38%

Upside

Reiterated

12/08/25

Kymera Therapeutics price target raised to $118 from $70 at LeerinkKymera Therapeutics price target raised to $118 from $70 at Leerink

Jeet Mukherjee

BTIG

$75→$138

Buy

57.16%

Upside

Reiterated

12/08/25

Kymera Therapeutics price target raised to $138 from $75 at BTIGKymera Therapeutics price target raised to $138 from $75 at BTIG

Tazeen Ahmad

Bank of America Securities

$71→$112

Buy

27.55%

Upside

Reiterated

12/08/25

Kymera Therapeutics' KT-621: Promising Market Potential and Competitive Positioning in Atopic Dermatitis Treatment

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Catanzaro

Mizuho Securities

$81→$120

Buy

36.66%

Upside

Reiterated

12/11/25

Kymera Therapeutics price target raised to $120 from $81 at MizuhoKymera Therapeutics price target raised to $120 from $81 at Mizuho

Sudan Loganathan

Stephens

$65→$110

Buy

25.27%

Upside

Reiterated

12/11/25

Kymera Therapeutics price target raised to $110 from $65 at StephensKymera Therapeutics price target raised to $110 from $65 at Stephens

Brian Cheng

J.P. Morgan

$70→$125

Buy

42.35%

Upside

Reiterated

12/10/25

Kymera Therapeutics: Promising Phase 1b Trial Results and Competitive Edge Drive Buy Rating

Andrew Fein

H.C. Wainwright

$84→$134

Buy

52.60%

Upside

Reiterated

12/09/25

Derek Archila

Wells Fargo

$69→$116

Buy

32.10%

Upside

Reiterated

12/09/25

Kymera Therapeutics price target raised to $116 from $69 at Wells FargoKymera Therapeutics price target raised to $116 from $69 at Wells Fargo

Srikripa Devarakonda

Truist Financial

$80→$116

Buy

32.10%

Upside

Reiterated

12/09/25

Kymera Therapeutics (KYMR) Gets a Buy from Truist Financial

Geoff Meacham

Citi

$80→$110

Buy

25.27%

Upside

Reiterated

12/09/25

Kymera Therapeutics price target raised to $110 from $80 at CitiKymera Therapeutics price target raised to $110 from $80 at Citi

Judah Frommer

Morgan Stanley

$73→$127

Buy

44.63%

Upside

Reiterated

12/09/25

Morgan Stanley Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)Given the size of these addressable populations, these changes take our 12‐month PT to $127 (vs. $73 prior).

Jeff Jones

Oppenheimer

$67→$120

Buy

36.66%

Upside

Reiterated

12/09/25

Kymera Therapeutics (KYMR) Receives a Buy from Oppenheimer

Clara Dong

Jefferies

$73→$122

Buy

38.94%

Upside

Reiterated

12/09/25

Kymera Therapeutics price target raised to $122 from $73 at JefferiesKymera Therapeutics price target raised to $122 from $73 at Jefferies

Edward Tenthoff

Piper Sandler

$98→$125

Buy

42.35%

Upside

Reiterated

12/09/25

Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Etzer Darout

Barclays

$70→$119

Buy

35.52%

Upside

Reiterated

12/08/25

Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

Faisal Khurshid

Leerink Partners

$70→$118

Buy

34.38%

Upside

Reiterated

12/08/25

Kymera Therapeutics price target raised to $118 from $70 at LeerinkKymera Therapeutics price target raised to $118 from $70 at Leerink

Jeet Mukherjee

BTIG

$75→$138

Buy

57.16%

Upside

Reiterated

12/08/25

Kymera Therapeutics price target raised to $138 from $75 at BTIGKymera Therapeutics price target raised to $138 from $75 at BTIG

Tazeen Ahmad

Bank of America Securities

$71→$112

Buy

27.55%

Upside

Reiterated

12/08/25

Kymera Therapeutics' KT-621: Promising Market Potential and Competitive Positioning in Atopic Dermatitis Treatment

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

1 Month

xxx

Success Rate

6/8 ratings generated profit

Average Return

+13.25%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +13.25% per trade.

3 Months

xxx

Success Rate

9/12 ratings generated profit

Average Return

+33.49%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +33.49% per trade.

1 Year

Jeet MukherjeeBTIG

Success Rate

8/9 ratings generated profit

Average Return

+91.67%

reiterated a buy rating 5 days ago

Copying Jeet Mukherjee's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +91.67% per trade.

2 Years

xxx

Success Rate

16/16 ratings generated profit

Average Return

+144.60%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +144.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KYMR has received 47 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 110.50.

Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$0.80 with a range of -$1.21 to -$0.35. The previous quarter’s EPS was -$0.94. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $14.62M with a range of $3.00M to $52.24M. The previous quarter’s sales results were $2.76M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Kymera Therapeutics’s 12-month average price target is 110.50.

What is KYMR’s upside potential, based on the analysts’ average price target?

Kymera Therapeutics has 25.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KYMR a Buy, Sell or Hold?

Kymera Therapeutics has a consensus rating of Strong Buy which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kymera Therapeutics’s price target?

The average price target for Kymera Therapeutics is 110.50. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $138.00 ,the lowest forecast is $68.00. The average price target represents 25.84% Increase from the current price of $87.81.

What do analysts say about Kymera Therapeutics?

Kymera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of KYMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

KYMR Analyst Ratings

KYMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kymera Therapeutics

KYMR Analyst Recommendation Trends

KYMR Financial Forecast

KYMR Earnings Forecast

KYMR Sales Forecast

KYMR Stock Forecast FAQ

Detailed List of Analyst Forecasts